最新の試験


EudraCT Number: 2022-001528-14 Sponsor Protocol Number: 67484703ADM2001 Start Date: 2023-02-02
Sponsor Name: Janssen-Cilag International NV
Full Title: A Phase 2a, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study to Evaluate the Efficacy, Safety and Tolerability of JNJ-67484703 in Participants with Atopic Dermatitis
Medical condition: Atopic Dermatitis
Disease: Version SOC Term Classification Code Term Level
21.1 100000004858 10003639 Atopic dermatitis LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Ongoing)
Trial results: (No results available)

EudraCT Number: 2022-003050-32 Sponsor Protocol Number: FAB122-CT-2201 Start Date: 2023-01-27
Sponsor Name: Ferrer Internacional, S.A.
Full Title: A multicenter, open-label extension study to investigate the long-term safety of FAB122 in patients with Amyotrophic Lateral Sclerosis
Medical condition: Amyotrophic Lateral Sclerosis (ALS)
Disease: Version SOC Term Classification Code Term Level
21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: ES (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-000439-22 Sponsor Protocol Number: 67953964MDD3001_VENTURA-1 Start Date: 2023-01-25
Sponsor Name: Janssen-Cilag International NV
Full Title: A Randomized, Double-blind, Multicenter, Parallel-Group, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants ...
Medical condition: Major Depressive Disorder (MDD)
Disease: Version SOC Term Classification Code Term Level
21.1 100000004873 10025453 Major depressive disorder NOS LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: CZ (Ongoing) ES (Ongoing) HU (Ongoing)
Trial results: (No results available)

EudraCT Number: 2021-005947-58 Sponsor Protocol Number: M1095-PSA-201 Start Date: 2023-01-25
Sponsor Name: MoonLake Immunotherapeutics AG
Full Title: Phase 2, Randomized, Parallel-group, Double-blind, Placebo-controlled Study of Sonelokimab in Patients with Active Psoriatic Arthritis
Medical condition: Active Psoriatic Arthritis
Disease: Version SOC Term Classification Code Term Level
21.0 100000004859 10037160 Psoriatic arthritis LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: CZ (Ongoing) ES (Ongoing) HU (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-001484-27 Sponsor Protocol Number: NL67672.091.18 Start Date: 2023-01-24
Sponsor Name: radboudumc
Full Title: B cell Activation in Sjögren's Syndrome, Cutaneous Lupus Erythematodus and Systemic Sclerosis Tissues Analysis 2
Medical condition: Systemic Sclerosis Sjögren's Syndrome Cutaneous Lupus Erythematodus
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: NL (Ongoing)
Trial results: (No results available)

EudraCT Number: 2022-002924-11 Sponsor Protocol Number: LOLAbiome Start Date: 2023-01-09
Sponsor Name: CBmed GmbH
Full Title: An observational study on the effect of L-ornithine-L-aspertate (LOLA) on the Flavonifractor abundance in the gut microbiome in liver cirrhosis
Medical condition: Liver cirrhosis with covert or overt hepatic encephalopathy (grade 0-2)
Disease: Version SOC Term Classification Code Term Level
20.0 100000004871 10024667 Liver cirrhosis LLT
20.0 100000004852 10014630 Encephalopathy hepatic LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: AT (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-000490-13 Sponsor Protocol Number: EstuEla2022 Start Date: 2023-01-09
Sponsor Name: OILS4CURE S.L
Full Title: Treatment, with a full spectrum extract of cannabis, in refractory epilepsy associated with tuberous sclerosis complex (TSC)
Medical condition: Refractory epilepsy in tuberous sclerosis complex
Disease: Version SOC Term Classification Code Term Level
Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
Trial protocol: ES (Ongoing)
Trial results: (No results available)

EudraCT Number: 2022-003079-41 Sponsor Protocol Number: BOLD-100-001 Start Date: 2023-01-06
Sponsor Name: Bold Therapeutics, Inc. (Bold)
Full Title: A Phase 1b/2a Dose Escalation Study of BOLD-100 in Combination with FOLFOX Chemotherapy in Patients with Advanced Solid Tumours
Medical condition: Colorectal Cancer Pancreatic Cancer Gastric Cancers Cholangiocarcinoma
Disease: Version SOC Term Classification Code Term Level
21.0 100000004864 10052362 Metastatic colorectal cancer LLT
21.1 100000004864 10033605 Pancreatic cancer metastatic LLT
20.1 100000004864 10017770 Gastric carcinoma LLT
21.1 100000004864 10077846 Cholangiocarcinoma metastatic LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: IE (Ongoing)
Trial results: (No results available)
EudraCT Number: 2021-004931-10 Sponsor Protocol Number: R3918-PNH-2050 Start Date: 2023-01-04
Sponsor Name: Regeneron Pharmaceuticals, Inc.
Full Title: An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Pozelimab and Cemdisiran Combination Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria
Medical condition: Paroxysmal nocturnal hemoglobinuria (PNH)
Disease: Version SOC Term Classification Code Term Level
21.1 100000004857 10055629 Paroxysmal nocturnal hemoglobinuria LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: GR (Ongoing) ES (Ongoing)
Trial results: (No results available)

EudraCT Number: 2022-001387-10 Sponsor Protocol Number: 220301 Start Date: 2022-12-29
Sponsor Name: TECNIMEDE, Sociedade Técnico-Medicinal, S.A.
Full Title: A Phase 3, Multicenter, Prospective, Placebo-Controlled, Randomized, Double-Blind Study to Assess the Efficacy and Safety of Favipiravir in Non-critical Hospitalized Patients with COVID-19 Pneumoni...
Medical condition: Coronavirus disease 2019 (COVID-19 pneumonia)
Disease: Version SOC Term Classification Code Term Level
25.1 100000004862 10066740 Acute respiratory tract infection LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: PT (Ongoing)
Trial results: (No results available)